ONCAlert | Upfront Therapy for mRCC

Genitourinary Cancers VIEW MORE >>

Cabazitaxel in combination with carboplatin demonstrated an improvement in progression-free survival in comparison with cabazitaxel alone in men with metastatic castration-resistant prostate cancer. Adverse events were more common with the combination regimen, but the doublet was generally well tolerated.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.